Please use this identifier to cite or link to this item:
Title: Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs
Authors: Chiu, G.N.C. 
Edwards, L.A.
Kapanen, A.I.
Malinen, M.M.
Dragowska, W.H.
Warburton, C.
Chikh, G.G.
Fang, K.Y.Y.
Tan, S.
Sy, J.
Tucker, C.
Waterhouse, D.N.
Klasa, R.
Bally, M.B.
Issue Date: Mar-2007
Citation: Chiu, G.N.C., Edwards, L.A., Kapanen, A.I., Malinen, M.M., Dragowska, W.H., Warburton, C., Chikh, G.G., Fang, K.Y.Y., Tan, S., Sy, J., Tucker, C., Waterhouse, D.N., Klasa, R., Bally, M.B. (2007-03). Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Molecular Cancer Therapeutics 6 (3) : 844-855. ScholarBank@NUS Repository.
Abstract: Various methods have been explored to enhance antibody-based cancer therapy. The use of multivalent antibodies or fragments against tumor antigens has generated a great deal of interest, as various cellular signals, including induction of apoptosis, inhibition of cell growth/ survival, or internalization of the surface molecules, can be triggered or enhanced on extensive cross-linking of the target/antibody complex by the multivalent form of the antibody. The goal of the studies reported here was to develop multivalent antibody constructs via grafting of antibody molecules onto liposome membranes to enhance antibody activity. Using trastuzumab and rituximab as examples, up to a 25-fold increase in the antibody potency in cell viability assay was observed when the antibodies were presented in the multivalent liposome formulation. Key cell survival signaling molecules, such as phosphorylated Akt and phosphorylated p65 nuclear factor-κB, were down-regulated on treatment with multivalent liposomal trastuzumab and liposomal rituximab, respectively. Potent in vivo antitumor activity was shown for liposomal trastuzumab. The data presented here showed the potential of liposome technology to enhance the therapeutic effect of antibodies via a mechanism that modulates cell survival through clustering of the target/ antibody complex. Copyright © 2007 American Association for Cancer Research.
Source Title: Molecular Cancer Therapeutics
ISSN: 15357163
DOI: 10.1158/1535-7163.MCT-06-0159
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on May 24, 2022


checked on May 17, 2022

Page view(s)

checked on May 12, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.